An interventional study of Temporal Interference Stimulation and Sham Temporal Interference Stimulation in Bipolar Depression, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University — 8 open to participants now, 8 under way, none of them phase 3. Bipolar Disorder · First Affiliated Hospital of Zhejiang University.
Among the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 10th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →8 of the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University are open now, in 1 country. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–45
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 15–55 · Healthy volunteers
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 16–65 · Healthy volunteers
By country, each count listing its studies:
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 94 across the 12 interventional studies, 960 across the 1 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.
4 of the studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07021508First Affiliated Hospital of Zhejiang UniversityEfficacy and Safety Assessment of Temporal Interference Stimulation to Improve Bipolar Depression | 2026-12 |
| NCT07589647First Affiliated Hospital of Zhejiang UniversityResearch on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic Disorders in Patients With Stable Bipolar Disorder Comorbid With Obesity | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
| NCT07414147First Affiliated Hospital of Zhejiang UniversityTMS for Improving Cognitive Function in Bipolar Disorder | 2027-03-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Bipolar Disorder by First Affiliated Hospital of Zhejiang University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study was to explore the efficacy and safety of temporal interference stimulation to improve bipolar depression, as well as to explore the corresponding neuroimaging mechanisms using magnetic resonance and electroencephalogram to provide novel intervention protocols and objective indicators of efficacy prediction for depressive episodes in bipolar disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Temporal Interference Stimulation
Device: Sham Temporal Interference Stimulation
A non-invasive, non-invasive method of deep brain electrical stimulation utilizing high-frequency electric field interactions to produce a low-frequency envelope to modulate neural activity.
The same machine was used as the temporal Interferenc real stimulus, with current creep only 20 seconds before stimulus onset to simulate the real stimulus sensation.
Montgomery-Asberg Depression Rating Scale(MADRS)
Montgomery-Asberg Depression Rating Scale (MADRS) is used to reflect the effect of antidepressant treatment and monitor the change of patients' condition. The scale is a separate scale, and the score should be based on clinical interviews. The symptoms should be asked from broad to detailed, so as to accurately score the severity. The rater must determine whether the score is on the defined score values (0,2,4,6) or between these scores (1,3,5), according to clinical practice. MADRS has a minimum value of 0 and a maximum value of 60, with larger scores representing poorer results.
Time frame: * "Baseline" * "Day 5" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Hamilton Depression Scale(HAMD-17)
The Hamilton Depression Scale(HAMD-17) was used to assess the extent of the patient's depressive episodes, with higher scores representing more severe depression, and this scale was used to monitor the patient's improvement in depression before and after treatment. HAMD-17 has a minimum value of 0 and a maximum value of 52, with larger scores representing poorer results.
Time frame: * "Baseline" * "Day 5" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Hamilton Anxiety Scale(HAMA)
The Hamilton Anxiety Scale is primarily used for the assessment of anxiety levels, and has 14 items, each of which has a 0-4 scale, with anxiety possible above a score of 7. HAMA has a minimum value of 0 and a maximum value of 56, with larger scores representing poorer results. The higher the score, the more severe the anxiety.
Time frame: * "Baseline" * "Day 5" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Young Mania Rating Scale(YMRS)
The Young Mania Rating Scale is mainly used to assess the manic symptoms of the subjects before and after the treatment, there are 11 items, each symptom has a working scale, divided into 5 levels, the level score of each item is different, most of them are 0-4, in which the 5th, 6th, 8th and 9th items are scored as 0, 2, 4, 6, 8, and the higher the total score of the subject the more serious the degree of mania. YMRS has a minimum value of 0 and a maximum value of 60, with larger scores representing poorer results.
Time frame: * "Baseline" * "Day 5" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Snaith-Hamilton Pleasure Scale(SHAPS)
The Snaith-Hamilton Pleasure Scale is a self-report scale that assesses the degree of the subject's pleasure deficit; the higher the score, the more severe their pleasure deficit. The scale was used to assess the degree of improvement in the patients' pleasure deficit before and after treatment. The minimum value of SHAPS is 14 and the maximum value is 56, with larger scores representing poorer results.
Time frame: * "Baseline" * "Day 5" * "1 week after the end of temporal interference stimulation" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Temporal Experience of Pleasure Scale (TEPS)
The Temporal Experience of Pleasure Scale (TEPS) is a self-report scale that assesses an individual's anticipation and experience of future pleasure, with higher scores suggesting a stronger experience of pleasure. The scale was used to evaluate the degree of improvement of pleasure deficit before and after treatment. The TEPS scale has a maximum value of 120 and a minimum value of 20. Lower scores indicate higher levels of pleasure deficit, while higher scores indicate higher levels of pleasure experience.
Time frame: * "Baseline" * "Day 5" * "1 week after the end of temporal interference stimulation" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR)
The Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) is a self-report scale with 16 items that is primarily used to assess patients' depressive symptoms. The QIDS-SR scale has a minimum value of 0 and a maximum value of 27, with higher scores indicating poorer results.
Time frame: * "Baseline" * "Day 1-5" * "1 week after the end of temporal interference stimulation" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Self-Rating Depression Scale (SDS)
The Self-Rating Depression Scale (SDS), a 20-item, 4-point scale, is used to assess the severity of an individual's depressive symptoms. The SDS scale has a maximum value of 100 and a minimum value of 25, with larger scores representing poorer results.
Time frame: * "Baseline" * "Day 5" * "1 week after the end of temporal interference stimulation" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Self-Rating Anxiety Scale (SAS)
The Self-Rating Anxiety Scale (SAS) contains 20 items reflecting subjective feelings of anxiety, and each item is rated on a four-point scale according to the frequency of the symptom, with 15 positive ratings and 5 negative ratings (marked with an asterisk \*), which allows the scale to rate the severity of anxiety symptoms and their change in treatment. The SAS scale has a maximum value of 100 and a minimum value of 25, with larger scores representing poorer results.
Time frame: * "Baseline" * "Day 5" * "1 week after the end of temporal interference stimulation" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
THINC-integrated tool (THINC-it)
THINC-it tool for assessing cognitive function changes in patients.
Time frame: * "Baseline" * "Day 5" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation"
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 19 months is below that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Zhejiang University →